The Medicines Co. (MDCO)

57.78
0.79 1.40
NASDAQ : Health Technology
Prev Close 56.99
Open 57.06
Day Low/High 56.06 / 57.73
52 Wk Low/High 16.69 / 57.43
Volume 1.18M
Avg Volume 2.06M
Exchange NASDAQ
Shares Outstanding 79.35M
Market Cap 4.44B
EPS -4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Medicines Co. Jumps on Pair of Bullish Notes

Medicines Co. Jumps on Pair of Bullish Notes

Positive results from Medicines Co.'s inclisiran drug prompt the bullish note from analysts.

The Medicines Company Announces Positive Topline Results For ORION-10 Phase 3 Study Of Inclisiran In ASCVD Patients

The Medicines Company Announces Positive Topline Results For ORION-10 Phase 3 Study Of Inclisiran In ASCVD Patients

The Medicines Company (NASDAQ: MDCO) today announced positive topline results for the ORION-10 Phase 3 clinical study in patients with atherosclerotic cardiovascular disease (ASCVD), successfully completing the pivotal Phase 3 LDL-cholesterol (LDL-C)...

The Medicines Company Announces Positive Topline Results For ORION-9 Phase 3 Study Of Inclisiran In Heterozygous Familial Hypercholesterolemia Patients

The Medicines Company Announces Positive Topline Results For ORION-9 Phase 3 Study Of Inclisiran In Heterozygous Familial Hypercholesterolemia Patients

The Medicines Company (NASDAQ: MDCO) today announced positive topline results for the ORION-9 Phase 3 clinical study in patients with Heterozygous Familial Hypercholesterolemia (HeFH).

Positive Developments for These 3 Biotech Stocks

Positive Developments for These 3 Biotech Stocks

We review Acadia Pharmaceuticals, The Medicines Company, and Flexion Therapeutics.

The Medicines Company Presents Results From ORION-11, First Phase 3 Trial Of Inclisiran, Showing Durable And Potent Lowering Of LDL-C With Twice-Yearly Dosing

The Medicines Company Presents Results From ORION-11, First Phase 3 Trial Of Inclisiran, Showing Durable And Potent Lowering Of LDL-C With Twice-Yearly Dosing

The Medicines Company (NASDAQ: MDCO) today announced the presentation of results from ORION-11, its first pivotal Phase 3 clinical study of inclisiran, an investigational twice-yearly therapy to reduce low-density lipoprotein cholesterol (LDL-C) and the...

These 5 Small Caps Are Well Positioned Despite Escalating Trade Tensions

These 5 Small Caps Are Well Positioned Despite Escalating Trade Tensions

They're the kind of names, along with a big dollop of cash in my portfolio, I plan to wait out the 'trade wars'.

Medicines Co. Rises on Positive Phase 3 Trial for Cholesterol Lowering Therapy

Medicines Co. Rises on Positive Phase 3 Trial for Cholesterol Lowering Therapy

The biopharmaceutical company reports positive Phase 3 trial results for its cholesterol-lowering therapy inclisiran.

The Medicines Company Announces Positive Topline Results From First Pivotal Phase 3 Trial Of Inclisiran

The Medicines Company Announces Positive Topline Results From First Pivotal Phase 3 Trial Of Inclisiran

The Medicines Company (NASDAQ: MDCO) today announced positive topline results from the first pivotal Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of inclisiran to decrease LDL-cholesterol (LDL-C) through twice-yearly dosing.

The Medicines Company Reports Second-Quarter 2019 Financial Results And Updates Clinical Development Program

The Medicines Company Reports Second-Quarter 2019 Financial Results And Updates Clinical Development Program

The Medicines Company (NASDAQ: MDCO) today reported financial results for the second quarter that ended June 30, 2019.

The Medicines Company To Announce Second Quarter 2019 Financial Results On July 24

The Medicines Company To Announce Second Quarter 2019 Financial Results On July 24

The Medicines Company (NASDAQ: MDCO) will host a conference call and audio webcast on Wednesday, July 24, 2019 at 8:30 a.

Notable Wednesday Option Activity: MDCO, DDS, GMS

Notable Wednesday Option Activity: MDCO, DDS, GMS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Medicines Co , where a total volume of 14,444 contracts has been traded thus far today, a contract volume which is representative of approximately 1.4 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 88.7% of MDCO's average daily trading volume over the past month, of 1.6 million shares.

The Medicines Company Announces Pricing Of Public Offering Of Common Stock

The Medicines Company Announces Pricing Of Public Offering Of Common Stock

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced the pricing of a public offering of 4,545,455 shares of its common stock at a public offering price of $33.

The Medicines Company Announces Launch Of Public Offering Of Common Stock

The Medicines Company Announces Launch Of Public Offering Of Common Stock

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced the launch of a public offering of $150.

The Medicines Company Presents Clinical Data Analyses For Inclisiran At 87th European Atherosclerosis Society Congress

The Medicines Company Presents Clinical Data Analyses For Inclisiran At 87th European Atherosclerosis Society Congress

The Medicines Company (NASDAQ: MDCO) today announced presentation of analyses of two clinical studies of inclisiran at the 87 th European Atherosclerosis Society (EAS) Congress in Maastricht, Netherlands.

These 3 Biotech Stocks Are Attracting Insider Buying

These 3 Biotech Stocks Are Attracting Insider Buying

What are insiders buying as the market sells off in recent trading sessions?

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating The Medicines Company For Potential Breaches Of Fiduciary Duty By Its Board Of Directors

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating The Medicines Company For Potential Breaches Of Fiduciary Duty By Its Board Of Directors

NEW YORK, May 20, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of The Medicines...

New Long-Term Data Show That Twice-a-Year Dosing With Inclisiran Results In Persistent Lowering Of LDL Cholesterol With No Material Safety Observations Out To Three Years

New Long-Term Data Show That Twice-a-Year Dosing With Inclisiran Results In Persistent Lowering Of LDL Cholesterol With No Material Safety Observations Out To Three Years

The Medicines Company (NASDAQ: MDCO) today announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing with inclisiran sodium 300 mg resulted in consistent lowering of low density...

June 2020 Options Now Available For Medicines (MDCO)

June 2020 Options Now Available For Medicines (MDCO)

Investors in Medicines Co saw new options become available today, for the June 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 401 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

The Medicines Company To Host Investor Conference Call And Webcast During National Lipid Association's 2019 Scientific Sessions

The Medicines Company To Host Investor Conference Call And Webcast During National Lipid Association's 2019 Scientific Sessions

The Medicines Company (NASDAQ:MDCO) will host a conference call and webcast for investors on Saturday, May 18, 2019, at 5:30 p.

The Medicines Company To Participate In The Bank Of America Merrill Lynch 2019 Healthcare Conference

The Medicines Company To Participate In The Bank Of America Merrill Lynch 2019 Healthcare Conference

The Medicines Company (NASDAQ:MDCO) announced that it will participate in the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, in Las Vegas.

The Medicines Company Reports First-Quarter 2019 Financial Results And Significant Progress With The Inclisiran Clinical Development Program

The Medicines Company Reports First-Quarter 2019 Financial Results And Significant Progress With The Inclisiran Clinical Development Program

The Medicines Company (NASDAQ:MDCO) today reported financial results for the first quarter that ended March 31, 2019.

The Medicines Company To Announce First Quarter 2019 Financial Results On April 25

The Medicines Company To Announce First Quarter 2019 Financial Results On April 25

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Thursday, April 25, 2019 at 8:30 a.

Insider Buying Is Still Alive and Well at These 3 Companies

Insider Buying Is Still Alive and Well at These 3 Companies

Insider purchases have tapered off from their frenzied pace in late 2018, but here are three names where such buying is evident.

The Medicines Company Reports Fourth-Quarter And Full Year 2018 Business And Financial Results

The Medicines Company Reports Fourth-Quarter And Full Year 2018 Business And Financial Results

The Medicines Company (NASDAQ: MDCO) today reported its financial results for the fourth quarter and full year ended December 31, 2018.

The Medicines Company Announces Upcoming Investor Conference Presentations

The Medicines Company Announces Upcoming Investor Conference Presentations

The Medicines Company (NASDAQ:MDCO) announced today that management will present company overviews at the following conferences: 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 9 a.

The Medicines Company To Announce Fourth-Quarter And Full-Year 2018 Financial Results On February 27

The Medicines Company To Announce Fourth-Quarter And Full-Year 2018 Financial Results On February 27

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, February 27, 2019, at 8:30 a.

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.

The Medicines Company Announces 5th Review Of Un-blinded Data And Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase 3 Trials

The Medicines Company Announces 5th Review Of Un-blinded Data And Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase 3 Trials

The Medicines Company (NASDAQ: MDCO) today announced that the 5 th review of un-blinded safety and efficacy data by the Independent Data Monitoring Committee (IDMC) for inclisiran Phase 3 trials has been completed.